Amplification of highly mutated human Ig lambda light chains from an HIV-1 infected patient.
暂无分享,去创建一个
Michel C Nussenzweig | M. Nussenzweig | H. Mouquet | N. Freund | J. Scheid | Hugo Mouquet | Johannes F Scheid | Natalia T Freund
[1] M. Nussenzweig,et al. AID targeting in antibody diversity. , 2011, Advances in immunology.
[2] Florian Klein,et al. Antibodies in HIV-1 Vaccine Development and Therapy , 2013, Science.
[3] Tongqing Zhou,et al. Structure-Based Stabilization of HIV-1 gp120 Enhances Humoral Immune Responses to the Induced Co-Receptor Binding Site , 2009, PLoS pathogens.
[4] M. Nussenzweig,et al. Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice , 2014, Cell.
[5] Ron Diskin,et al. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.
[6] F. Pereyra,et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. , 2009, The Journal of infectious diseases.
[7] J. Mascola,et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques , 2014, The Journal of experimental medicine.
[8] Tongqing Zhou,et al. Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization , 2013, Cell.
[9] M. Nussenzweig,et al. Predominant Autoantibody Production by Early Human B Cell Precursors , 2003, Science.
[10] Michel C Nussenzweig,et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. , 2008, Journal of immunological methods.
[11] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.
[12] Florian Klein,et al. Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy , 2014, Cell.
[13] Ron Diskin,et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice , 2012, Nature.
[14] Ron Diskin,et al. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120 , 2012, Proceedings of the National Academy of Sciences.
[15] J. Mascola,et al. Most rhesus macaques infected with the CCR5-tropic SHIVAD8 generate cross-reactive antibodies that neutralize multiple HIV-1 strains , 2012, Proceedings of the National Academy of Sciences.
[16] F. Pereyra,et al. A method for identification of HIV gp140 binding memory B cells in human blood. , 2009, Journal of immunological methods.
[17] M. Nussenzweig,et al. Memory B Cell Antibodies to HIV-1 gp140 Cloned from Individuals Infected with Clade A and B Viruses , 2011, PloS one.
[18] M. Nussenzweig,et al. Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity , 2014, Cell.
[19] Maxim N. Artyomov,et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation , 2010, Nature.
[20] C. Milstein,et al. Mutation Drift and Repertoire Shift in the Maturation of the Immune Response , 1987, Immunological reviews.
[21] C. Milstein,et al. The Dynamic Nature of the Antibody Repertoire , 1988, Immunological reviews.
[22] Florian Klein,et al. Computational analysis of anti–HIV-1 antibody neutralization panel data to identify potential functional epitope residues , 2013, Proceedings of the National Academy of Sciences.
[23] Richard T. Wyatt,et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals , 2009, Nature.
[24] M. Nussenzweig,et al. Autoreactivity in human IgG+ memory B cells. , 2007, Immunity.